June 07, 2018 | FAH Policy Blog Team
Category: FAH News, Legislation, Medicare, Pharmaceuticals
A wide ranging coalition of 46 groups, that include FAH, from across the health care spectrum sent a letter today to leaders of the Senate Judiciary Committee urging swift action on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974).
The legislation is a bipartisan, market-based reform that will speed the introduction of generic and biosimilar competition for brand-name drugs.
The letter lays out the case for the bill saying, “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs. The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over ten years.”
You can read the entire letter by clicking here.
- New Report Shows Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals
- FAH Leader Expresses Opposition to Ruling that Overturns 340B Medicare Regulation
- FAH, AHA Send Joint Letter to Congress on Surprise Billing
- FAH Comments on Proposed Rule Expanding Use of HRAs